Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
M. Feldmann,R. Maini,5 Authors,T. Hussell
2020 · DOI: 10.1016/S0140-6736(20)30858-8
The Lancet · 492 Citations
TLDR
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) gains access to host cells via angiotensin-converting enzyme 2, which is expressed in the type II surfactant-secreting alveolar cells of the lungs.